The use of active surveillance or watchful waiting increased by more than twofold overall between 2010 and 2020 among patients with intermediate-risk prostate cancer. Current guidelines support active ...

The CAPTAIN trial shows faster recovery, fewer complications, and better early function with the minimally invasive therapy in men with intermediate-risk prostate cancer.

For men with intermediate risk prostate cancer, radiation treatment with brachytherapy alone can result in similar cancer control with fewer long-term side effects, when compared to more aggressive ...

SAN FRANCISCO, September 29, 2025 — For patients with intermediate-risk, localized prostate cancer, radiation therapy delivered in five sessions reduced patient-reported side effects compared to ...

For patients with intermediate-risk, localized prostate cancer, radiation therapy delivered in five sessions reduced patient-reported side effects compared to longer courses of radiation, according to ...

Alessa Therapeutics ("Alessa"), a clinical-stage biopharmaceutical company advancing novel localized drug delivery technology for the treatment of early-stage prostate cancers, announced the ...

Adding 6 months of neoadjuvant deprivation therapy (NADT) doesn’t seem to add any benefit for patients with intermediate-risk prostate cancer treated with external-beam radiation therapy (EBRT), ...

The rate of active surveillance as initial treatment increased from 2.0% in 2010 to 8.6% in 2020. The use of active surveillance in patients with intermediate-risk prostate cancer has increased in ...

The findings, published in JAMA Network Open, were reported by Cristian Udovicich of the Odette Cancer Centre at Sunnybrook Health Sciences Centre, Toronto, Canada, and colleagues. The investigators ...

Effect of testosterone treatment in hypogonadal men on prostate cancer risk: Results of a prospective comparative study—8 years follow-up analysis to age-matched controls. This is an ASCO Meeting ...

Autonomic nerve invasion may be simple method of identifying which patients with intermediate-risk T3a prostate cancer who have negative surgical margins after radical prostatectomy are at increased ...

Vanquish uses ultrasound, transurethral and electromagnetically guided thermotherapy to ablate prostate tissue.